my take, page-9

re: us the sheep................. Rocker1 - not wishing to get in an arguement with you and the 12month delay in FDA approval is obviuolsy a big negative. But what were the deficiencies in the application are you suggesting? Thats all I'm asking.

If mangement took the other route for approval then application would of required an extensive clinical trial (much more extensive than ay clincial data the FDA has now requested) and cost money that CCE didn't have and if they did go down that route you can bet it would be a lot longer that 12 more months before approval.

Woth regard to Sparki grumbling about mangement being overpaid, I can tell you the executive team will certianly be required to earn their dollars over the next 12 months. As for the direcotrs ( and I was opposed to them getting the options) the options will prob be worthless nwo.